Vaccines and immunotherapeutics using IL-28 and compositions and methods of using the same
View Patent ↗Compositions, recombinant vaccines and live attenuated pathogens comprising one or more isolated nucleic acid molecules that encode an immunogen in combination with an isolated nucleic acid molecule that encodes IL-28 or a functional fragment thereof are disclosed. Methods of inducing an immune response in an individual against an immunogen, using such compositions are disclosed.
1. A recombinant immunogenic pharmaceutical composition comprising an immunogenic amount of an isolated nucleic acid construct comprising a nucleotide sequence that encodes a viral protein operably linked to regulatory elements, wherein said nucleic acid construct further comprises a nucleotide sequence that encodes an IgE signal peptide and a codon-optimized and RNA-optimized nucleotide sequence that encodes IL-28B or a functional fragment thereof, wherein said viral protein is from a virus selected from the group consisting of: influenza virus, human immunodeficiency virus, hepatitis C virus, West Nile Virus and hepatitis B virus.
2. An injectable immunogenic pharmaceutical composition comprising the composition of claim 1 .
3. The recombinant immunogenic pharmaceutical composition of claim 1 , wherein the viral protein is from an influenza virus.
4. The recombinant immunogenic pharmaceutical composition of claim 1 , wherein the viral protein is from HIV.
5. The recombinant immunogenic pharmaceutical composition of claim 4 wherein said recombinant pharmaceutical composition comprises a recombinant vaccinia vector.
6. A method of inducing an immune response in an individual against a viral protein from a virus selected from the group consisting of: influenza virus, human immunodeficiency virus, hepatitis C virus, West Nile Virus and hepatitis B virus comprising administering to said individual a recombinant vaccine of claim 1 .
7. A live attenuated virus comprising an isolated nucleic acid construct comprising a nucleotide sequence that encodes a viral protein operably linked to regulatory elements, wherein said nucleic acid construct further comprises a nucleotide sequence that encodes an IgE signal peptide and a codon-optimized and RNA-optimized nucleotide sequence that encodes IL-28B or a functional fragment thereof.
8. A method of immunizing an individual against a pathogen comprising administering to said individual the live attenuated pathogen of claim 7 .
9. The recombinant immunogenic pharmaceutical composition of claim 1 , wherein the nucleotide sequence that encodes IL-28B or a functional fragment thereof is operably linked to a promoter.
10. The recombinant immunogenic pharmaceutical composition of claim 9 , wherein the promoter is a SV40 promoter, MMTV promoter, L TR promoter, or CMV immediate early promoter.
11. The live attenuated virus of claim 7 , wherein the virus is an influenza virus.
12. The live attenuated virus of claim 7 , wherein the virus is human immunodeficiency virus, hepatitis C virus, West Nile Virus or a hepatitis B virus.
13. An immunogenic pharmaceutical composition comprising an immunogenic amount of a nucleic acid construct comprising a nucleotide sequence that encodes a viral protein operably linked to regulatory elements, wherein said nucleic acid construct further comprises a nucleotide sequence that encodes an IgE signal peptide and a codon-optimized and RNA-optimized nucleotide sequence that encodes IL-28B or a functional fragment thereof.
14. The immunogenic pharmaceutical composition of claim 13 , wherein the viral protein is from a virus selected from the group consisting of: influenza virus, human immunodeficiency virus, hepatitis C virus, West Nile Virus and hepatitis B virus.
15. An injectable immunogenic pharmaceutical composition comprising the pharmaceutical composition of claim 13 .
16. A recombinant immunogenic pharmaceutical composition comprising
an immunogenic amount of an isolated nucleic acid construct comprising a nucleotide sequence that encodes a viral protein operably linked to regulatory elements, wherein said viral protein is from a virus selected from the group consisting of: influenza virus, human immunodeficiency virus, hepatitis C virus, West Nile Virus and hepatitis B virus; and
an immunogenic amount of an isolated nucleic acid construct encoding an IgE signal peptide and a codon-optimized and RNA-optimized immunomodulating protein, wherein the immunomodulating protein consists of IL28B or a fragment thereof.